Juno Therapeutics (JUNO) is one of the casualties that occurred during the 59th American Society of Hematology (ASH) Annual Meeting. The stock experienced undeserved selloff except for the fact that it had a deserved rally that we believe will remain as long as the firm is spending effort towards improving its cancer treatment. This cancer treatment is the living genetically engineered chimeric antigen receptor (CAR) T cell expected to treat or maybe cure various cancers. CAR T, safety, efficacy and reachability to solid tumors, however, need to be improved to reach its ultimate goals, which are extremely ambitious . . .